UVE - UNIVERSAL HLDGS （）

In Friday’s session, Universal Insurance Holdings Inc. (NYSE:UVE) marked $10.59 per share, up from $10.45 in the previous session. While Universal Insurance Holdings Inc. has overperformed by 1.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UVE fell by -36.30%, with highs and lows ranging from […]

Universal Insurance Plc. has bagged the 2022 PEARL Awards for Listed Company with Highest Earnings Yield.The underwriter was announced the winner by the organisers of the award at a ceremony held in Lagos. The post Universal Insurance bags Pearl Award appeared first on The Guardian Nigeria News - Nigeria and World News .

Universal Insurance (UVE) declares $0.16/share quarterly dividend, in line with previous.Forward yield 6.39%Payable Dec. 16; for shareholders of record Dec. 9; ex-div Dec. 8.Universal…

Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars MOUNTAIN VIEW, Calif. , Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard "Ric" Peterson as chief financial officer. Richard "Ric" Peterson, a biotech industry veteran, has been named chief financial officer of Turn Biotechnologies. Mr. Peterson, who has served as CFO of numerous public and private biotech and pharmaceutical companies, has deep experience with private financing, public offerings, and complex global transactions. He will oversee all financial functions and fundraising efforts as Turn Bio prepares to launch its clinical programs. "Ric''s background with biotech companies in various stages of development and his experience as a financial and business leader will be great assets as Turn Bio moves into the next phases of growth," said company CEO Anja Krammer . "As Turn Bio progresses toward the clinic, Ric will enhance our team''s expertise and help communicate our unique vision for treating the diseases of aging within the investment community." During his 25 years of serving as a chief financial officer, Peterson has led traditional fundraising efforts for pre-clinical, clinical and commercial companies, managed initial public offerings and overseen corporate purchases and sales.

Universal Insurance Holdings, Inc. (NYSE:NYSE:UVE) Q3 2022 Earnings Conference Call October 28, 2022 10:00 AM ET Company Participants Arash Soleimani – Chief Strategy Officer Steve Donaghy…

In Friday’s session, Universal Insurance Holdings Inc. (NYSE:UVE) marked $10.59 per share, up from $10.45 in the previous session. While Universal Insurance Holdings Inc. has overperformed by 1.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UVE fell by -36.30%, with highs and lows ranging from […]

Universal Insurance Plc. has bagged the 2022 PEARL Awards for Listed Company with Highest Earnings Yield.The underwriter was announced the winner by the organisers of the award at a ceremony held in Lagos. The post Universal Insurance bags Pearl Award appeared first on The Guardian Nigeria News - Nigeria and World News .

Universal Insurance (UVE) declares $0.16/share quarterly dividend, in line with previous.Forward yield 6.39%Payable Dec. 16; for shareholders of record Dec. 9; ex-div Dec. 8.Universal…

Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars MOUNTAIN VIEW, Calif. , Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard "Ric" Peterson as chief financial officer. Richard "Ric" Peterson, a biotech industry veteran, has been named chief financial officer of Turn Biotechnologies. Mr. Peterson, who has served as CFO of numerous public and private biotech and pharmaceutical companies, has deep experience with private financing, public offerings, and complex global transactions. He will oversee all financial functions and fundraising efforts as Turn Bio prepares to launch its clinical programs. "Ric''s background with biotech companies in various stages of development and his experience as a financial and business leader will be great assets as Turn Bio moves into the next phases of growth," said company CEO Anja Krammer . "As Turn Bio progresses toward the clinic, Ric will enhance our team''s expertise and help communicate our unique vision for treating the diseases of aging within the investment community." During his 25 years of serving as a chief financial officer, Peterson has led traditional fundraising efforts for pre-clinical, clinical and commercial companies, managed initial public offerings and overseen corporate purchases and sales.

Universal Insurance Holdings, Inc. (NYSE:NYSE:UVE) Q3 2022 Earnings Conference Call October 28, 2022 10:00 AM ET Company Participants Arash Soleimani – Chief Strategy Officer Steve Donaghy…

Universal Insurance (UVE) declares $0.16/share quarterly dividend, in line with previous.Forward yield 6.39%Payable Dec. 16; for shareholders of record Dec. 9; ex-div Dec. 8.Universal…

Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars MOUNTAIN VIEW, Calif. , Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard "Ric" Peterson as chief financial officer. Richard "Ric" Peterson, a biotech industry veteran, has been named chief financial officer of Turn Biotechnologies. Mr. Peterson, who has served as CFO of numerous public and private biotech and pharmaceutical companies, has deep experience with private financing, public offerings, and complex global transactions. He will oversee all financial functions and fundraising efforts as Turn Bio prepares to launch its clinical programs. "Ric''s background with biotech companies in various stages of development and his experience as a financial and business leader will be great assets as Turn Bio moves into the next phases of growth," said company CEO Anja Krammer . "As Turn Bio progresses toward the clinic, Ric will enhance our team''s expertise and help communicate our unique vision for treating the diseases of aging within the investment community." During his 25 years of serving as a chief financial officer, Peterson has led traditional fundraising efforts for pre-clinical, clinical and commercial companies, managed initial public offerings and overseen corporate purchases and sales.

Universal Insurance Holdings, Inc. (NYSE:NYSE:UVE) Q3 2022 Earnings Conference Call October 28, 2022 10:00 AM ET Company Participants Arash Soleimani – Chief Strategy Officer Steve Donaghy…

Universal Insurance press release (UVE): Q3 Non-GAAP EPS of -$2.27.Revenue of $312.81M (+8.9% Y/Y).The GAAP operating loss margin was 29.3%, down from a GAAP operating income margin…

Universal Insurance (UVE) is scheduled to announce Q3 earnings results on Thursday, October 27th, after market close.The consensus EPS estimate is -$2.51 (-498.4% Y/Y) and consensus…